MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
JBIO — Jade Biosciences, Inc. Common Stock
NasdaqJade Biosciences, Inc. Common Stock
$14.07
-0.05(-0.35%)
- O
- 14.21
- H
- 14.71
- L
- 13.79
- V
- 607.05K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About JBIO
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateApr 29, 2025
Employees55
Stock ExchangeNasdaq
Ticker SymbolJBIO
Key Financial Statistics
| Market Cap | $898.00M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $8.36 - $28.00 |
| 52-Week Avg Volume | 639.8K |
| VWAP | $14.16 |
| Transactions | 9,096 |
| Total Recorded Bars | 1,322 days |